(December 1, 2017, 9:17 AM EST) -- PHILADELPHIA — A Pennsylvania state appeals panel on Nov. 28 affirmed the dismissal of 13 Risperdal gynecomastia cases, agreeing with a trial judge that the plaintiffs’ claims are preempted by Michigan’s drug shield law and that the plaintiffs could not prove that the fraud exception applied to their claims (In Re: Risperdal Litigation, MA.J.L., et al v. Janssen Pharmaceuticals Inc., et al., No. 55 EDA 2015, et al., Pa. Super., 2017 Pa. Super. LEXIS 965)....